Legend Biotech (LEGN) Gains from Investment Securities (2020 - 2025)
Legend Biotech (LEGN) posted Gains from Investment Securities of -$877000.0 for Q3 2025, up 74.01% on a QoQ basis from -$3.4 million in Q4 2024, and down 101.42% year-over-year from $61.9 million in Q3 2024.
Legend Biotech (LEGN) has 6 years of Gains from Investment Securities data on file, last reported at -$877000.0 in Q3 2025.
- In Q3 2025, Gains from Investment Securities fell 101.42% year-over-year to -$877000.0; the TTM figure through Sep 2025 stood at $56.7 million (down 6.06% YoY), while the FY2023 annual figure was -$663000.0, down 11.8% from the prior year.
- Gains from Investment Securities improved to -$877000.0 in Q3 2025, from -$3.4 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $61.9 million in Q3 2024 and bottomed at -$3.4 million in Q4 2024.
- A 5-year average of $6.2 million and a median of -$593000.0 in 2022 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 185.11% in 2021, down 3800.0% in 2021.
- Year by year, Gains from Investment Securities stood at $40000.0 in 2021, then plunged by 1582.5% to -$593000.0 in 2022, then decreased by 11.8% to -$663000.0 in 2023, then tumbled by 408.9% to -$3.4 million in 2024, then soared by 74.01% to -$877000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$877000.0 (Q3 2025), -$3.4 million (Q4 2024), and $61.9 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -877,000.00 |
| Sep 30, 2025 | -877,000.00 |
| Dec 31, 2024 | -3.37 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Sep 30, 2024 | 61.90 Mn |
| Sep 30, 2024 | 61.90 Mn |
| Jun 30, 2024 | -918,000.00 |
| Jun 30, 2024 | -918,000.00 |
| Mar 31, 2024 | 71,000.00 |
| Mar 31, 2024 | 71,000.00 |
| Dec 31, 2023 | -663,000.00 |
| Dec 31, 2023 | -663,000.00 |
| Dec 31, 2022 | -593,000.00 |
| Dec 31, 2022 | -593,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | -39,000.00 |
| Sep 30, 2021 | -39,000.00 |
| Dec 31, 2020 | -47,000.00 |
| Dec 31, 2020 | -47,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Sep 30, 2020 | -1,000.00 |